• Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients 

      Tsolaki V., Mantzarlis K., Mpakalis A., Malli E., Tsimpoukas F., Tsirogianni A., Papagiannitsis C., Zygoulis P., Papadonta M.-E., Petinaki E., Makris D., Zakynthinos E. (2020)
      Data on the effectiveness of ceftazidime-avibactam (CAZ-AVI) in critically ill, mechanically ventilated patients are limited. The present retrospective observational cohort study, which was conducted in two general intensive ...
    • Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry 

      Diamantopoulos P.T., Pappa V., Symeonidis A., Kotsianidis I., Galanopoulos A., Papadaki H., Anagnostopoulos A., Vassilopoulos G., Zikos P., Hatzimichael E., Papaioannou M., Megalakaki A., Kotsopoulou M., Repousis P., Dimou M., Solomou E., Pontikoglou C., Kyriakakis G., Tsokanas D., Papoutselis M.-K., Papageorgiou S., Kourakli A., Panayiotidis P., Viniou N.-A. (2020)
      Background: Hypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible treatment goal. Patients and Methods: We analyzed data from patients with MDS ...
    • Circulating suPAR associates with severity and in-hospital progression of COVID-19 

      Chalkias A., Skoulakis A., Papagiannakis N., Laou E., Tourlakopoulos K., Pagonis A., Michou A., Ntalarizou N., Mermiri M., Ragias D., Bernal-Morell E., Cebreiros López I., García de Guadiana-Romualdo L., Eugen-Olsen J., Gourgoulianis K., Pantazopoulos I., Chalkias A., Skoulakis A., Laou E., Michou A., Ntalarizou N., Mermiri M., Ragias D., Tourlakopoulos K., Pagonis A., Gourgoulianis K., Pantazopoulos I., Papagiannakis N., Kampolis C., García de Guadiana-Romualdo L., Albaladejo-Otón M.D., Rodríguez Mulero M.D., Galindo Martínez M., Hernández Olivo M., Campos Rodríguez V., Cebreiros López I., Arnaldos Carrillo M., Noguera Velasco J.A., Pascual Figal D.A., Bernal-Morell E., Alcaraz García A., Alcaraz García M.J., Martínez Martínez M., Esteban-Torrella P., Sancho-Rodríguez N., Eugen-Olsen J., for the SPARCOL Investigators (2022)
      Background: COVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other ...